INVO Fertility, Inc. (IVF) Form 10-Q — Aug 14, 2026
INVO Fertility reported Q2 2026 revenue of $2.18 million, up 16.7% year over year, and quarterly net income of $888,740 — though that profit came from a $2.45 million gain on remeasuring its pre-existing stake in the HRCFG buyout rather than operations. First-half revenue rose 19.7% to $4.19 million while the net loss narrowed to $4.65 million from $21.0 million a year ago. The 10-Q carries explicit going-concern language, citing substantial doubt about the company's ability to continue as a going concern.
Key figures
- Eps
- -$2.48 basic/diluted for H1 2026; Q2 2026: $0.42 basic / $0.35 diluted
- Revenue
- 4190710
- Total Debt
- 1643073
- Revenue Yoy
- +19.7% (H1 2026 vs H1 2025)
- Total Assets
- 25834562
- Cash Position
- 3732945
- Shares Outstanding
- 2506969
- Hrcfg goodwill
- 2732332
- Q2 2026 revenue
- 2175485
- Q2 2026 net income
- 888740
- Accumulated deficit
- 96035618
- Q2 2026 revenue yoy
- +16.7%
- Stockholders equity
- 16491578
- Gain on remeasurement hrcfg
- 2452032
- Indiana clinic purchase price
- 760000
- Reverse splits since mar 2025
- 1-for-12 (Mar 2025), 1-for-3 (Jul 2025), 1-for-8 (Nov 2025), 1-for-5 (Mar 2026)
- Nti note receivable fair value
- 5169284
- Hrcfg acquisition consideration
- 1576050
- Warrant inducement net proceeds h1 2026
- 7100000
Price after filing
Close on the filing date to close N calendar days later (from $0.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.